Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemoglobin maintenance in pediatric ESRD patients by ferric pyrophosphate citrate (Triferic)
2019-003140-71Phase 3Completed
- Sponsor
- Rockwell Medical
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ferric pyrophosphate in iron deficiency anemia (IDA), end-stage kidney disease (ESKD) and chronic kidney disease (CKD), sponsored by Rockwell Medical. Primary endpoint: Safety (adverse events). Started Apr 2020; status: completed.
02
Drugs
ferric pyrophosphate
03
Conditions
iron deficiency anemia (IDA)end-stage kidney disease (ESKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2019-003140-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003140-71.